Estrogen receptors evolution in neoadjuvant aromatase inhibitor (AI) therapy for breast cancer in elderly women: Stability of hormonal receptor expression during treatment

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 29, Issue 4, 2006, Pages 385-388

  Salmon, R J ^a   Alran, S ^a   Malka, I ^a   De Cremoux, P ^a   Rosty, C ^a   Languille, O ^a   Campana, F ^a  

^a INSTITUT CURIE   (France)

Author keywords

Breast cancer

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; NITRILE; TRIAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; BONE METASTASIS; BREAST BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER STAGING; CONSERVATIVE TREATMENT; DRUG CAPSULE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECHOGRAPHY; FEMALE; FOLLOW UP; FRANCE; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MASTECTOMY; PROTEIN EXPRESSION; TREATMENT DURATION; TUMOR VOLUME; ADJUVANT THERAPY; BREAST TUMOR; CLINICAL TRIAL; METABOLISM; MIDDLE AGED;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NITRILES; RECEPTORS, ESTROGEN; TRIAZOLES;

EID: 33746835020     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/01.coc.0000225397.24909.33     Document Type: Article

References (26)

1. Bradbeer JW, Kingdom J. Primary treatment of breast cancer in elderly women with Tamoxifène. Clin Oncol. 1983;9:31-34.
2. Foudraine NA, Verhoef LC, Burghouts JT. Tamoxifène as sole therapy for primary breast cancer in the elderly patient. Eur J Cancer. 1992;28A:900-903.
3. Heroin JM, Price PE, Dear JA, et al. Long-term follow-up of elderly patients with loco regional breast cancer treated with Tamoxifène only. Br J Surg. 1991;78:213-217.
4. Gazet JC, Markopoulos CH, Ford HT, et al. Prospective randomized trial of tamoxifen versus surgery in elderly patients with breast cancer. Lancet. 1988;1:679-681.
5. Williams MR, Gilson D, Marsh L, et al. The early results from a randomized study of radiotherapy versus Nolvadex as initial treatment for stage III breast cancer. Eur J Surg Oncol. 1988;14:235-240.
6. Salmon RJ, Remvikos Y, Campana F, et al. Neoadjuvant tamoxifen in post menopausal patients with operable breast cancer. Eur J Surg Oncol. 2003;29:831-834.
7. Smith IE, Dowsett M, on behalf of the IMPACT trialists. Comparison of anastrozole vs tamoxifen alone or in combination as neoadjuvant treatment of estrogen receptor-positive (ER+) operable breast cancer in postmenopausal women: the IMPACT trial. Breast Cancer Res Treat. 2003;82(suppl S60):Abstract 1-2.
8. Dixon JM, Jackson J, Hills M, et al. Anastrozole demonstrates clinical and biological effectiveness in estrogen receptor-positive breast cancers, irrespective of the erbB2 status. Eur J Cancer. 2004;40:2742-2747.
9. Morandi P, Rouzier R, Altundag K, et al. The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma. Cancer. 2004;101:1482-1488.
10. Smith IE, Dowsett M. Drug therapy: aromatase inhibitors in breast cancer. N Engl J Med. 2003;348:2431-2442.
11. Brodie AM, Njar VC. Aromatase inhibitors and their application in breast cancer treatment. Steroids. 2000;65:171-179.
12. Johnston SR, Dowsett M. Aromatase inhibitors for breast cancer, lessons from the laboratory. Nat Rev Cancer. 2003;3:821-831.
13. Freedman OC, Verma S, Clemons MJ. Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution. Cancer Treat Rev. 2005;31:1-17.
14. Zhu L, Chow LW, Loo WT, Guan XY, Toi M. Her2/neu expression predicts the response to anti-aromatase neo-adjuvant therapy in primary breast cancer. Clin Cancer Res. 2004;10:4639-4644.
15. Bershtein LM, Poroshina TE, Zimarina TS, et al. Expression of estrogen receptors-alpha and beta in primary breast neoplasms and tumors exposed to neo-adjuvant hormonal therapy. Bull Exp Biol Med. 2004;138:494-496.
16. Harper-Wynne CL, Sacks NP, Shenton K, et al. Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer. J Clin Oncol. 2002;20:1026-1035.
17. Dixon JM. Role of endocrine therapy in the neo-adjuvant setting. Ann Surg Oncol. 2004;11(suppl):18S.
18. Milla-Santos A, Milla L, Calvo N, et al. Anastrozole as neoadjuvant therapy for patients with hormone-dependent, locally-advanced breast cancer. Anticancer Res. 2004;24:1315-1318.
19. Domont J, Namer M, Khayat D, et al. Traitement hormonal néo-adjuvant du cancer du sein. Bull Cancer. 2004;91:55-62.
20. Ingle JN, Suman VJ. Aromatase inhibitors vs tamoxifen for management of postmenopausal breast cancer in the advanced disease and neo-adjuvant settings. J Steroid Biochem Mol Biol. 2003;86:313-319.
21. Mauriac L, Debled M, Durand M, et al. Neo-adjuvant tamoxifen for hormone sensitive non-metastatic breast carcinomas in early post-menopausal women. Ann Oncol. 2002;13:293-298.
22. Aihara T, Munakata S, Morino H, et al. Feasibility of sentinel nodebiopsy for breast cancer after neoadjuvant endocrine therapy: a pilot study. J Surg Oncol. 2004;85:77-81.
23. Ellis MJ. Neoadjuvant endocrine therapy as a drug development strategy. Clin Cancer Res. 2004;10:391S-3915S.
24. Dowsett M, Harper Wyne C, Boeddinghaus I, et al. HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res. 2001;61:8452-8458.
25. Dowsett M, Smith IE, Ebbs SR, et al. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res. 2005;11:951s-958s.
26. Van de Vijver M. Gene expression profiling and the future of adjuvant therapy. Oncologist. 2005;10(suppl 2):30-34.